Background Pimecrolimus cream I% has been shown to effectively control atopic eczema (AE) when applied twice daily from the first signs or symptoms of AE until clearance. Moreover, pimecrolimus cream 1% has a favourable safety profile, lacking topical corticosteroid-related side-effects such as skin atrophy, making it particularly useful to treat delicate body regions (e.g. the face). Objective The objective of this naturalistic study was to monitor the safety, tolerability and efficacy of pimecrolimus when used in the long-term management of AE in a real-life setting. Methods A multicentre, open-label study was conducted in 2034 patients aged >= 3 months with mild to moderate AE for up to 12 months' duration. Patients applied pimecrolimus cream twice daily, initiating treatment at first signs or symptoms of AE, continuing until clearance. Results Patients (n = 1847; 91 %) completed 3 months of the study. Treatment success (clear or almost clear AE) after 3 months of treatment was observed on the whole body in 59% of patients and on the face in 81 % of patients. Disease improvement of whole body and face was seen in 77% and 63% of patients, respectively. Pruritus was absent or mild in 79% of patients. Pimecrolimus cream was well tolerated throughout the study. Conclusion In a daily practice setting, pimecrolimus cream 1 % effectively and safely controls AE.

Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study / J. Ring, A. Abraham, C. de Cuyper, K. Kim, T. Langeland, V. Parra, P. Pigatto, T. Reunala, R. Szczepanski, M. Möhrenschlager, M. Bräutigam, A. B. Rossi, E. Meents-Kopecky, D. Schneider. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - 22:2(2008 Feb), pp. 195-203.

Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study

P. Pigatto;
2008

Abstract

Background Pimecrolimus cream I% has been shown to effectively control atopic eczema (AE) when applied twice daily from the first signs or symptoms of AE until clearance. Moreover, pimecrolimus cream 1% has a favourable safety profile, lacking topical corticosteroid-related side-effects such as skin atrophy, making it particularly useful to treat delicate body regions (e.g. the face). Objective The objective of this naturalistic study was to monitor the safety, tolerability and efficacy of pimecrolimus when used in the long-term management of AE in a real-life setting. Methods A multicentre, open-label study was conducted in 2034 patients aged >= 3 months with mild to moderate AE for up to 12 months' duration. Patients applied pimecrolimus cream twice daily, initiating treatment at first signs or symptoms of AE, continuing until clearance. Results Patients (n = 1847; 91 %) completed 3 months of the study. Treatment success (clear or almost clear AE) after 3 months of treatment was observed on the whole body in 59% of patients and on the face in 81 % of patients. Disease improvement of whole body and face was seen in 77% and 63% of patients, respectively. Pruritus was absent or mild in 79% of patients. Pimecrolimus cream was well tolerated throughout the study. Conclusion In a daily practice setting, pimecrolimus cream 1 % effectively and safely controls AE.
Adults; Atopic dermatitis; Atopic eczema; Children; Eczema; Infants; Naturalistic; Open-label; Pimecrolimus
Settore MED/35 - Malattie Cutanee e Veneree
Article (author)
File in questo prodotto:
File Dimensione Formato  
Ring_et_al-2008-Journal_of_the_European_Academy_of_Dermatology_and_Venereology.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 136.77 kB
Formato Adobe PDF
136.77 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/188769
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 17
social impact